Invasive strategy does not improve survival in kidney disease patients with ischemia
29 August 2022

In patients with advanced chronic kidney disease and chronic coronary disease, an invasive strategy does not reduce the five-year risk of death compared to a conservative strategy. That's the finding of late breaking research presented in a Hot Line session on 29 August at ESC Congress 2022.

Previous trials of an invasive versus conservative strategy for the management of chronic coronary disease have excluded patients with advanced chronic kidney disease or included only a small proportion of these patients. Therefore, the optimal management of this high risk group of patients is unknown.

The primary results of the ISCHEMIA-CKD trial have been previously reported. The trial enrolled 777 patients with advanced chronic kidney disease (defined as estimated glomerular filtration rate}